CN115569197A - Mdm2抑制剂的间歇给药 - Google Patents

Mdm2抑制剂的间歇给药 Download PDF

Info

Publication number
CN115569197A
CN115569197A CN202211129314.2A CN202211129314A CN115569197A CN 115569197 A CN115569197 A CN 115569197A CN 202211129314 A CN202211129314 A CN 202211129314A CN 115569197 A CN115569197 A CN 115569197A
Authority
CN
China
Prior art keywords
mdm2i
weeks
treatment
dose
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202211129314.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·费雷蒂
S·杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115569197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN115569197A publication Critical patent/CN115569197A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202211129314.2A 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药 Withdrawn CN115569197A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
US62/017,406 2014-06-26
CN201580034558.4A CN106456635A (zh) 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580034558.4A Division CN106456635A (zh) 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药

Publications (1)

Publication Number Publication Date
CN115569197A true CN115569197A (zh) 2023-01-06

Family

ID=53510950

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580034558.4A Withdrawn CN106456635A (zh) 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药
CN202211129314.2A Withdrawn CN115569197A (zh) 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580034558.4A Withdrawn CN106456635A (zh) 2014-06-26 2015-06-25 Mdm2抑制剂的间歇给药

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR20240110659A (enExample)
CN (2) CN106456635A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3197477A4 (en) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
CA3043004A1 (en) * 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
AU2018242612B2 (en) 2017-03-31 2020-05-21 Novartis Ag Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
US11639355B2 (en) 2018-03-12 2023-05-02 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
BR112020018755A2 (pt) 2018-03-20 2021-01-05 Novartis Ag Combinações farmacêuticas
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
EP3801476A4 (en) * 2018-05-25 2022-07-06 Kartos Therapeutics, Inc. METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
TW202123941A (zh) 2019-09-16 2021-07-01 瑞士商諾華公司 Ｍｄｍ２抑制劑用於治療骨髓纖維化之用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EA014445B1 (ru) 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
UA108746C2 (xx) * 2009-12-22 2015-06-10 Заміщені ізохінолінони та хіназолінони
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2361667B1 (en) 2010-02-25 2015-04-01 Alstom Technology Ltd A wet scrubber and a method of cleaning a process gas
AU2011326395B2 (en) * 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
KR20130088170A (ko) * 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
HRP20170797T1 (hr) 2011-08-11 2017-08-11 Estetra S.P.R.L. Primjena estetrola kao hitnog kontraceptiva
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US9371568B2 (en) 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
ES2785203T3 (es) 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
WO2015097622A1 (en) 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN108025006A (zh) 2015-02-06 2018-05-11 尤尼蒂生物技术公司 化合物及在治疗衰老相关病症中的用途
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
CA3043004A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
SI3544982T1 (sl) 2016-11-22 2022-02-28 Novartis Ag Kemijski postopek za pripravo derivatov imidazopirolidinona in njihovih vmesnih spojin
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
AU2018242612B2 (en) 2017-03-31 2020-05-21 Novartis Ag Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
US11406627B2 (en) 2017-10-12 2022-08-09 Novartis Ag Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
BR112020018755A2 (pt) 2018-03-20 2021-01-05 Novartis Ag Combinações farmacêuticas
ES2986421T3 (es) 2018-10-30 2024-11-11 Dana Farber Cancer Inst Inc Método de tratamiento de tumores P53 WT
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
US20220175682A1 (en) 2019-04-04 2022-06-09 Novartis Ag Siremadlin Succinate

Also Published As

Publication number Publication date
RU2017102319A3 (enExample) 2019-02-12
IL249138B (en) 2020-09-30
US11419870B2 (en) 2022-08-23
ES2856210T3 (es) 2021-09-27
US20170196866A1 (en) 2017-07-13
WO2015198266A1 (en) 2015-12-30
SG11201609853VA (en) 2017-01-27
JP6728072B2 (ja) 2020-07-22
KR20240110659A (ko) 2024-07-15
TN2016000522A1 (en) 2018-04-04
IL249138A0 (en) 2017-01-31
EP3160463A1 (en) 2017-05-03
TW201613576A (en) 2016-04-16
EP3160463B1 (en) 2020-10-21
MX2016017075A (es) 2017-05-03
JP2017519019A (ja) 2017-07-13
KR102462177B1 (ko) 2022-11-04
BR112016029750A2 (pt) 2017-08-22
CA2953079C (en) 2023-05-02
CA2953079A1 (en) 2015-12-30
US20180110779A1 (en) 2018-04-26
US20190209561A1 (en) 2019-07-11
CL2016003295A1 (es) 2017-07-28
AU2015278765B2 (en) 2018-08-16
KR20170017932A (ko) 2017-02-15
US20240261284A1 (en) 2024-08-08
PH12016502556A1 (en) 2017-04-17
KR20220151027A (ko) 2022-11-11
US20220233530A9 (en) 2022-07-28
AU2015278765A1 (en) 2017-01-19
RU2017102319A (ru) 2018-07-26
US20210000824A1 (en) 2021-01-07
CN106456635A (zh) 2017-02-22
US20230092181A1 (en) 2023-03-23
RU2695228C2 (ru) 2019-07-22

Similar Documents

Publication Publication Date Title
US20230092181A1 (en) Intermittent dosing of mdm2 inhibitor
JP7427212B2 (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
KR102845148B1 (ko) Her2 양성 암의 치료
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
US9815845B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
WO2021175824A1 (en) Method for administration of an anti cancer agent
JP2016502974A (ja) Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
Zhao et al. Construction and Preclinical evaluation of BCL3-Degrading PROTACs for Enhanced Colorectal Cancer Therapy
US20220071982A1 (en) Methods and uses for treating cancer
CA3244127A1 (en) USE OF NIRAPARIB FOR THE TREATMENT OF BRAIN CANCER
EP4499069A2 (en) Indolium compounds for treating cancer
JP2024509887A (ja) Ｅｐ３００分解剤および神経芽細胞腫におけるその使用
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20230106